JUPITER Trial
Jump to navigation
Jump to search
|
Low Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
JUPITER Trial On the Web |
|
American Roentgen Ray Society Images of JUPITER Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Click here to download slides for JUPITER.
Overview
This most recent trial randomly assigned 17,802 healthy subjects with LDL < 130 mg/dL and high-sensitivity CRP > 2 g/L to Rosuvastatin 20 mg daily or placebo. A significant reduction in the composite and individual components of the primary end-point of myocardial infarction, stroke, arterial revascularization hospitalization for unstable angina or death from cardiovascular causes and all-cause mortality was noted and trial was stopped earlier at 1.9 years (maximum of 5 years)[1].
References
- ↑ Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ; et al. (2008). "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein". N Engl J Med. 359 (21): 2195–207. doi:10.1056/NEJMoa0807646. PMID 18997196. Review in: Evid Based Med. 2009 Apr;14(2):48 Review in: Ann Intern Med. 2009 Jan 20;150(2):JC1-4